TABLE 1.
Baseline patient and disease characteristics of the patients with PSC
| All patients n = 201 | Scheduled cohort n = 133 | On-demand cohort n=68 | P-value on-demand vs. scheduled cohort | |
|---|---|---|---|---|
| Gender | ||||
| Male | 141 (70) | 92 (69) | 49 (72) | 0.672 |
| Female | 60 (30) | 41 (31) | 19 (28) | — |
| Median age at initial diagnosis (range) | 31 (10, 67) | 31 (10, 67) | 31 (10, 65) | 0.804 |
| Median time between initial diagnosis and initial presentation (y) | 3 (0, 36) | 2 (0, 36) | 4 (0, 23) | 0.120 |
| Follow-up (y) | 8 (0, 21) | 7 (0, 21) | 10 (0, 21) | 0.123 |
| Mean BMI (SD) | 24 (± 3.9) | 24 (± 3.9) | 23 (± 3.8) | 0.021 |
| Comorbidities | ||||
| Arterial hypertension | 41 (20) | 28 (21) | 13 (19) | 0.747 |
| Diabetes | 8 (4) | 5 (4) | 3 (4) | 0.823 |
| Asthma/COPD | 8 (4) | 4 (3) | 4 (6) | 0.324 |
| Overlap syndrome with AIH | 22 (11) | 13 (10) | 9 (13) | 0.457 |
| Presence of liver cirrhosis | 95 (48) | 56 (41) | 40 (59) | 0.026 |
| Presence of IBD | 154 (77) | 97 (73) | 57 (84) | 0.084 |
| Ulcerative colitis | 129 (64) | 78 (59) | 51 (75) | — |
| Crohn’s disease | 19 (10 | 15 (11) | 4 (6) | — |
| Undetermined | 6 (3) | 4 (3) | 2 (3) | — |
| UDCA a | 196 (99) | 130 (99) | 66 (99) | 0.627 |
| Median number of ERCPs performed per patient (range) | 5 (1, 40) | 7 (2, 40) | 2 (1, 12) | <0.001 |
| Relevant stenosis b | 150 (75) | 106 (80) | 44 (66) | 0.031 |
| Manifestation c | 0.389 | |||
| Exclusively intrahepatic | 69 (35) | 42 (32) | 27 (41) | — |
| Exclusively extrahepatic | 30 (15) | 22 (17) | 8 (12) | — |
| Intrahepatic and extrahepatic | 100 (50) | 69 (52) | 31 (47) | — |
| Stent implantation per patient | 36 (18) | 22 (17) | 14 (21) | 0.479 |
| Stent implantation per intervention | 52/794 (7) | 35/615 (6) | 17/179 (9) | 0.471 |
| Median baseline laboratory parameters (Min-Max) | ||||
| Bilirubin [mg/dL] | 0.8 (0.19, 27.7) | 0.8 (0.19, 11.7) | 0.85 (0.29, 27.7) | 0.838 |
| ALT [U/L] | 59 (9, 599) | 64 (9, 599) | 53 (14, 346) | 0.067 |
| AST [U/L] | 51 (17, 384) | 54 (17, 384) | 46 (19, 237) | 0.167 |
| ALP [U/L] | 217 (49, 872) | 218 (61, 798) | 208 (49, 872) | 0.917 |
| GGT [U/L] | 184 (8, 1463) | 191 (10, 1463) | 163 (8, 1312) | 0.279 |
| Creatinine [mg/dL] | 0.83 (0.39, 1.7) | 0.84 (0.4, 1.7) | 0.8 (0.5, 1.23) | 0.141 |
| INR | 1 (0.85, 2.55) | 1 (0.9, 1.5) | 1 (0.9, 2.55) | 0.529 |
| MELD | 7 (6, 28) | 7 (6, 20) | 8 (6, 28) | 0.078 |
| MRS | −0.17 (−2.2, 2.78) | −0.26 (−2.2, 2.78) | 0.16 (−2, 2.64) | 0.412 |
Notes: Data are n (%) of patients, if not indicated otherwise. The percentages were rounded and may not sum 100%. Significant results (P < 0.05) are shown in bold type.
Laboratory reference values: Bilirubin < 1.2 mg/dL, ALT < 31 U/L, AST 35 U/L, ALP 35–105 U/L, GGT 5–36 U/L, creatinine 0.5–0.96 mg/dL, INR 0.9–1.25.
UDCA treatment was analyzed in 260 patients; 131 patients in the scheduled cohort and 67 patients in the on-demand cohort.
Relevant stenosis was analyzed in 200 patients; 133 patients in the scheduled cohort and 67 patients in the on-demand cohort.
Manifestation of stenosis was analyzed in 199 patients; 133 patients in the scheduled cohort and 66 patients in the on-demand cohort.
Abbreviations: AIH, autoimmune hepatitis; ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate aminotransferase; BMI, body mass index; COPD, chronic obstructive pulmonary disease; ERCP, Endoscopic retrograde cholangiopancreaticography; GGT, gamma-glutamyl transferase; IBD, inflammatory bowel disease; INR, international normalized ratio; MELD, Model for End-Stage Liver Disease; MRS, Mayo risk score; UDCA, ursodeoxycholic acid.